Company attributes
Other attributes
Stelvio Therapeutics is a privately held, biotechnology company based in San Diego, California that was founded in 2017 by Attila Hajdu. The company focuses on developing a pipeline of alternative treatments for malignant glioblastoma multiforme (GBM), the most common and lethal brain tumor.
Stelvio's approach to treating cancer involves identifying compounds that drive the differentiation of cancer stem cells into benign cell types. It then induces the differentiation of tumor propagating cells into non-tumorigenic cells.
In March 2018, Stelvio Therapeutics joined Johnson & Johnson Innovation JLABS. Around the same time, i2020 Accelerator announced that Stelvio had joined its early drug discovery ecosystem to advance its proprietary epigenetic platform for glioblastoma therapies. i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year framework. It
On May 5, 2017 Stevlio Therapeutics completed their seed funding round with and undisclosed amount of funding from SOSV and IndieBio.
